Clinical trial
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After…
NCT00168818 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00168818 |
|---|---|
| Title | Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery |
| Official title | A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism, Arthroplasty, Replacement, Hip |
| Intervention type | Drug |
| Interventions | dabigatran etexilate, enoxaparin |
| Enrollment | 3,494 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | May 19, 2014 |
| Countries | Australia, Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway and 4 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: